Crowdonomics
This isn’t Knightscope’s most recent raise. Reg A+ · Debt · Aug 2023 (Closed) is more current.View latest round
Knightscope

Reg A+ · Equity · Nov 2016

ClosedReg A+Equity
via SI Securities, LLC · last checked Aug 17, 2026View campaign
Raised
$18.7M / $16.5M max
100% of ceiling
Investors
—
—
Estimated pre-money
$71.3M
—

Financials disclosed in this offering

FY2015 · hover for source
$30K
−$3.4M
FY2015
RevenueNet income
Metric
FY2015 audited
Income statement
Revenue
$29,770
Cost of goods sold
$81,447
Gross margin
-174%
Net income
-$3,392,277
Balance sheet
Cash
$6,141,642
Accounts receivable
$32,738
Total assets
$7,418,877
Long-term debt
$61,625
Total liabilities
$1,296,094
Other
Headcount
25

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Amendments to this offering

2 amendments
  1. Dec 21, 2016
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗
  2. Dec 7, 2016
    Terms not yet extracted from this filing
    Form 1-A/A on EDGAR ↗

Each line compares the amendment with the previous filing of this offering. Form 1-A amendments state no reason; those filed before qualification are usually responses to SEC staff review.

Deal terms

Est. pre-money$71.3M
Price / share$3.00
Price / share today$150.00
Shares offered5,500,000

Estimated, not stated: $3.00 × 23,768,598 securities outstanding.

$3.00 as sold; $150.00 after the Sep 2024 split (1:50) (Form 10-Q, p. 1).

Offering details

Target—
Max$16,500,000
Min investment$999
OpenedNov 7, 2016
Deadline—
ClosedMay 21, 2019
Days active925

Links & provenance

Source: SEC EDGAR
0001144204-16-131843
Last synced Aug 17, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.